This segment focuses on the development of novel, non-opioid therapies for the treatment of neuropathic pain, addressing a significant unmet medical need. The lead candidate, LX9211, is currently in Phase 2 clinical development for diabetic peripheral neuropathic pain (DPNP). Research and development activities include preclinical studies to elucidate the mechanism of action, clinical trials to assess safety and efficacy, and biomarker discovery to identify patient populations most likely to benefit from treatment. The segment leverages advanced pain research methodologies, including quantitative sensory testing and patient-reported outcomes, to evaluate treatment response. Future opportunities include expanding the indications for LX9211 to other types of neuropathic pain and exploring combination therapies to enhance pain relief.

This segment is dedicated to developing innovative treatments for cardiovascular and metabolic diseases, with a focus on heart failure and diabetes. The primary asset in this segment is Sotagliflozin, an orally-delivered small molecule drug candidate that has completed Phase 3 clinical trials for the treatment of heart failure and type 1 diabetes. Research and development efforts include post-marketing studies to evaluate long-term safety and efficacy, as well as exploring new formulations and delivery methods to improve patient adherence. The segment utilizes advanced cardiovascular imaging techniques and metabolic profiling to assess treatment effects. Future opportunities include expanding the indications for Sotagliflozin to other cardiovascular and metabolic disorders and developing combination therapies to address multiple risk factors.